GLP-1 plus 5-Amino-1MQ: bold stack or borrowed hype?

What did @genxshopfinds76 actually say?

A nurse practitioner on TikTok claimed that combining GLP-1 medications with 5-Amino-1MQ can prevent muscle loss, boost energy, shrink fat cells, improve insulin sensitivity, and support "NAD and sirtuins" for anti-aging. She called it "the sidekick your GLP-1 did not know it needed" and said she stacks it in her clinical protocols at a telehealth practice called Vital Balance 10.

The pitch is aimed squarely at GLP-1 users who feel "skinny fat, sluggish, or like your muscles packed their bags," which is a real and documented concern with rapid weight loss from semaglutide or tirzepatide. That framing is savvy marketing, because the problem she's describing is genuine. The solution she's selling is a lot less certain.

She is also actively recruiting patients in Ohio and expanding her license to ten additional states, which means this video functions as both health content and a direct patient acquisition ad.

Does the science back this up?

Weakly, and mostly in preclinical settings. The human evidence for 5-Amino-1MQ specifically is thin to nonexistent for most of these claims. This is not a compound with robust randomized controlled trial data in humans.

5-Amino-1MQ is a small-molecule NNMT (nicotinamide N-methyltransferase) inhibitor. NNMT regulates NAD+ metabolism and has been studied as a potential target for obesity and metabolic dysfunction. A 2021 study by Neelakantan et al. in Nature Communications showed that NNMT inhibition in mice reduced fat mass and improved metabolic markers without caloric restriction. That is genuinely interesting science.

But mice are not people. There are no published Phase 2 or Phase 3 human trials on 5-Amino-1MQ for fat loss, muscle preservation, or insulin sensitivity. The compound is not FDA-approved, not on any compounding pharmacy's FDA-approved list, and is largely sold in research-grade or gray-market form. Claiming it "preserves muscle while you're losing fat" as if this is established clinical fact is a significant overreach from where the evidence actually sits.

On the GLP-1 muscle-loss concern: that problem is real. Studies including Bikou et al. (2023, NEJM Evidence) have confirmed that lean mass loss accompanies GLP-1-driven weight reduction, and resistance training is the most evidence-backed mitigation strategy currently available.

What did they get wrong (or right)?

Credit where it is due: the underlying concern about muscle loss on GLP-1s is legitimate, and flagging NAD-sirtuin pathways as relevant to metabolic aging is not nonsense. NNMT inhibition as a concept has real scientific interest behind it.

What she gets wrong is the confidence. Saying 5-Amino-1MQ "reduces fat cell size" and "improves insulin sensitivity" in humans is stated as fact when it is extrapolated from animal models. That is a meaningful distinction that a nurse practitioner promoting a paid clinical service should not be glossing over.

She also does not mention that 5-Amino-1MQ is not FDA-approved, is not on the 503A or 503B compounding lists for human use, and has no established human dosing protocols backed by clinical trials. Framing it as a routine clinical "stack" without those disclosures is the kind of omission that should concern anyone considering signing up.

• She accurately identifies that GLP-1-induced muscle loss is a documented clinical problem.
• She accurately references NAD and sirtuin pathways as relevant to metabolic health, though she implies more certainty than the science supports.
• She inaccurately presents preclinical mouse data as if it translates directly to human clinical outcomes.
• She does not disclose the unapproved status of 5-Amino-1MQ or the absence of human trial data.

What should you actually know?

If you are losing muscle on a GLP-1, the intervention with the most actual human evidence behind it is resistance training combined with adequate dietary protein, not an unapproved NNMT inhibitor. A 2022 analysis by Cava et al. in Obesity Reviews found that protein intake and progressive resistance exercise are the primary evidence-based tools for lean mass preservation during caloric restriction.

5-Amino-1MQ may turn out to be genuinely useful. The science is interesting. But "may turn out to be useful" and "stack it in my clinical protocols" are two very different things, and patients deserve to know the difference before signing up with a telehealth provider selling this as a solution.

A few practical points worth knowing before you consider any peptide or research compound stack:

• Ask whether the compound is FDA-approved or on a recognized compounding list. If the answer is neither, that is a meaningful regulatory and safety consideration.
• Ask what human clinical trial data supports the specific claims being made, not mouse model data.
• Be cautious when a health content creator is simultaneously recruiting you as a paying patient. That is a conflict of interest worth naming.
• Muscle loss on GLP-1s is real, and your provider should be discussing protein targets and resistance training as first-line tools, not experimental compounds.